{
    "info": {
        "nct_id": "NCT03569280",
        "official_title": "A First-in-Human Study to Determine the Safety, Pharmacokinetics and Efficacy of KPG-121 When Administered With Enzalutamide, Abiraterone, or Apalutamide in Subjects With Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer",
        "inclusion_criteria": "1. Signed informed consent provided prior to any study-related procedure being performed;\n2. Able to swallow and retain orally administered medication;\n3. Male aged 18 years and older;\n4. diagnosis of prostate carcinoma;\n5. Men with either non-metastatic or metastatic CRPC are eligible;\n6. Completed at least 4 or more weeks of prior continuous therapy with fixed stable dose enzalutamide, abiraterone or apalutamide prior to initiating study treatment (for Part 1), or with fixed stable dose enzalutamide (for Part 2), with no change in dose for at least 2 weeks prior to screening;\n7. Serum testosterone level <50 ng/dL (<0.5 ng/mL, <7.0 nmol/L).\n8. ECOG performance status of 0 or 1;\n9. Adequate baseline organ function;\n10. Must have a QT interval corrected for heart rate according to Fridericia's formula (QTcF) <470 milliseconds (msec) or <480 msec with bundle branch block;\n11. Male subject with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from time of screening until 3 months after the last dose of study medication;\n12. Willing and able to comply with all protocol required visits and assessments.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "1. Prior chemotherapy, radiation;\n2. Prior malignancy other than CRPC.\n3. Uncontrolled hypothyroidism, or TSH >2.0 x ULN at screening.\n4. Current use of or anticipated requirement of prohibited medication(s);\n5. Any unresolved â‰¥grade 2 (per CTCAE v5.0) toxicity from previous anti-cancer therapy;\n6. Previous history of difficulty swallowing capsules;\n7. Known active infection requiring intravenous (IV);\n8. Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test ;\n9. History of seizure or any condition that may predispose subject to seizure (e.g., prior cortical stroke or significant brain trauma). History of loss of consciousness or transient ischemic attack within 12 months prior to the start of study medication;\n10. Poorly controlled hypertension;\n11. Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs\n12. History or evidence of cardiovascular risk; known cardiac metastases;\n13. Previous major surgery within 30 days prior to the start of study medication;",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "4. diagnosis of prostate carcinoma;",
            "criterions": [
                {
                    "exact_snippets": "diagnosis of prostate carcinoma",
                    "criterion": "prostate carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Able to swallow and retain orally administered medication;",
            "criterions": [
                {
                    "exact_snippets": "Able to swallow and retain orally administered medication",
                    "criterion": "ability to swallow and retain orally administered medication",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Male aged 18 years and older;",
            "criterions": [
                {
                    "exact_snippets": "Male",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "aged 18 years and older",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Men with either non-metastatic or metastatic CRPC are eligible;",
            "criterions": [
                {
                    "exact_snippets": "Men",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "non-metastatic or metastatic CRPC",
                    "criterion": "castration-resistant prostate cancer (CRPC)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "non-metastatic or metastatic",
                    "criterion": "metastatic status of CRPC",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "non-metastatic",
                                "metastatic"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Completed at least 4 or more weeks of prior continuous therapy with fixed stable dose enzalutamide, abiraterone or apalutamide prior to initiating study treatment (for Part 1), or with fixed stable dose enzalutamide (for Part 2), with no change in dose for at least 2 weeks prior to screening;",
            "criterions": [
                {
                    "exact_snippets": "Completed at least 4 or more weeks of prior continuous therapy with fixed stable dose enzalutamide, abiraterone or apalutamide prior to initiating study treatment (for Part 1)",
                    "criterion": "prior continuous therapy with enzalutamide, abiraterone or apalutamide (Part 1)",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "dose stability",
                            "expected_value": "fixed stable dose"
                        }
                    ]
                },
                {
                    "exact_snippets": "with fixed stable dose enzalutamide (for Part 2)",
                    "criterion": "prior continuous therapy with enzalutamide (Part 2)",
                    "requirements": [
                        {
                            "requirement_type": "dose stability",
                            "expected_value": "fixed stable dose"
                        }
                    ]
                },
                {
                    "exact_snippets": "no change in dose for at least 2 weeks prior to screening",
                    "criterion": "dose change prior to screening",
                    "requirements": [
                        {
                            "requirement_type": "duration without dose change",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Serum testosterone level <50 ng/dL (<0.5 ng/mL, <7.0 nmol/L).",
            "criterions": [
                {
                    "exact_snippets": "Serum testosterone level <50 ng/dL (<0.5 ng/mL, <7.0 nmol/L)",
                    "criterion": "serum testosterone level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "ng/dL"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 0.5,
                                "unit": "ng/mL"
                            }
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 7.0,
                                "unit": "nmol/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. ECOG performance status of 0 or 1;",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Signed informed consent provided prior to any study-related procedure being performed;",
            "criterions": [
                {
                    "exact_snippets": "Signed informed consent provided prior to any study-related procedure being performed",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to any study-related procedure being performed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. Adequate baseline organ function;",
            "criterions": [
                {
                    "exact_snippets": "Adequate baseline organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "baseline",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "10. Must have a QT interval corrected for heart rate according to Fridericia's formula (QTcF) <470 milliseconds (msec) or <480 msec with bundle branch block;",
            "criterions": [
                {
                    "exact_snippets": "QT interval corrected for heart rate according to Fridericia's formula (QTcF) <470 milliseconds (msec)",
                    "criterion": "QTcF (QT interval corrected for heart rate according to Fridericia's formula)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 470,
                                "unit": "msec"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "QT interval corrected for heart rate according to Fridericia's formula (QTcF) ... <480 msec with bundle branch block",
                    "criterion": "QTcF (QT interval corrected for heart rate according to Fridericia's formula) with bundle branch block",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 480,
                                "unit": "msec"
                            }
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": "bundle branch block"
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Male subject with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from time of screening until 3 months after the last dose of study medication;",
            "criterions": [
                {
                    "exact_snippets": "Male subject with a female partner of childbearing potential",
                    "criterion": "subject sex and partner fertility status",
                    "requirements": [
                        {
                            "requirement_type": "subject sex",
                            "expected_value": "male"
                        },
                        {
                            "requirement_type": "partner fertility status",
                            "expected_value": "female of childbearing potential"
                        }
                    ]
                },
                {
                    "exact_snippets": "must have either had a prior vasectomy",
                    "criterion": "vasectomy status",
                    "requirements": [
                        {
                            "requirement_type": "history of vasectomy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "or agree to use effective contraception from time of screening until 3 months after the last dose of study medication",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use effective contraception",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "contraception duration",
                            "expected_value": "from time of screening until 3 months after the last dose of study medication"
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. Willing and able to comply with all protocol required visits and assessments.",
            "criterions": [
                {
                    "exact_snippets": "Willing ... to comply with all protocol required visits and assessments",
                    "criterion": "willingness to comply with protocol visits and assessments",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "able to comply with all protocol required visits and assessments",
                    "criterion": "ability to comply with protocol visits and assessments",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "Must be MALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "10. Poorly controlled hypertension;",
            "criterions": [
                {
                    "exact_snippets": "Poorly controlled hypertension",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": "poorly controlled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Any unresolved â‰¥grade 2 (per CTCAE v5.0) toxicity from previous anti-cancer therapy;",
            "criterions": [
                {
                    "exact_snippets": "Any unresolved â‰¥grade 2 (per CTCAE v5.0) toxicity from previous anti-cancer therapy",
                    "criterion": "toxicity from previous anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "resolution status",
                            "expected_value": "unresolved"
                        },
                        {
                            "requirement_type": "severity grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "CTCAE v5.0"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "9. History of seizure or any condition that may predispose subject to seizure (e.g., prior cortical stroke or significant brain trauma). History of loss of consciousness or transient ischemic attack within 12 months prior to the start of study medication;",
            "criterions": [
                {
                    "exact_snippets": "History of seizure",
                    "criterion": "seizure",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any condition that may predispose subject to seizure (e.g., prior cortical stroke or significant brain trauma)",
                    "criterion": "condition predisposing to seizure",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prior cortical stroke",
                    "criterion": "cortical stroke",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "significant brain trauma",
                    "criterion": "significant brain trauma",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of loss of consciousness ... within 12 months prior to the start of study medication",
                    "criterion": "loss of consciousness",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "transient ischemic attack within 12 months prior to the start of study medication",
                    "criterion": "transient ischemic attack",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test ;",
            "criterions": [
                {
                    "exact_snippets": "Presence of hepatitis B surface antigen (HBsAg)",
                    "criterion": "hepatitis B surface antigen (HBsAg)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "positive hepatitis C antibody test",
                    "criterion": "hepatitis C antibody",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Known active infection requiring intravenous (IV);",
            "criterions": [
                {
                    "exact_snippets": "Known active infection requiring intravenous (IV)",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment_requirement",
                            "expected_value": "requiring intravenous (IV)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Previous history of difficulty swallowing capsules;",
            "criterions": [
                {
                    "exact_snippets": "Previous history of difficulty swallowing capsules",
                    "criterion": "difficulty swallowing capsules",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Prior chemotherapy, radiation;",
            "criterions": [
                {
                    "exact_snippets": "Prior chemotherapy",
                    "criterion": "prior chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "radiation",
                    "criterion": "prior radiation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Prior malignancy other than CRPC.",
            "criterions": [
                {
                    "exact_snippets": "Prior malignancy other than CRPC",
                    "criterion": "prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": {
                                "operator": "!=",
                                "value": 1,
                                "unit": "CRPC"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "12. History or evidence of cardiovascular risk; known cardiac metastases;",
            "criterions": [
                {
                    "exact_snippets": "History or evidence of cardiovascular risk",
                    "criterion": "cardiovascular risk",
                    "requirements": [
                        {
                            "requirement_type": "history or evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known cardiac metastases",
                    "criterion": "cardiac metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "11. Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs",
            "criterions": [
                {
                    "exact_snippets": "known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs",
                    "criterion": "hypersensitivity reaction or idiosyncrasy to drugs",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Uncontrolled hypothyroidism, or TSH >2.0 x ULN at screening.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypothyroidism",
                    "criterion": "hypothyroidism",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "TSH >2.0 x ULN at screening",
                    "criterion": "TSH level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.0,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Current use of or anticipated requirement of prohibited medication(s);",
            "criterions": [
                {
                    "exact_snippets": "Current use of ... prohibited medication(s)",
                    "criterion": "prohibited medication use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "anticipated requirement of prohibited medication(s)",
                    "criterion": "prohibited medication use",
                    "requirements": [
                        {
                            "requirement_type": "anticipated requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "13. Previous major surgery within 30 days prior to the start of study medication;",
            "criterions": [
                {
                    "exact_snippets": "Previous major surgery within 30 days prior to the start of study medication",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}